Global Rare Biomarkers Specimen Collection and Stabilization Market Size Study by Biomarker and End Use, and Regional Forecasts 2022-2032

Description

The Global Rare Biomarkers Specimen Collection and Stabilization Market, valued at approximately USD 36.69 billion in 2023, is projected to experience exponential growth, achieving a CAGR of 14.4% over the forecast period 2024-2032. This market growth is primarily fueled by advancements in precision medicine and the increasing focus on early detection and monitoring of rare diseases and cancer. With innovations in biomarker technology, such as circulating cell-free DNA (ccfDNA) and circulating tumor cells (CTCs), the market is witnessing a paradigm shift toward non-invasive diagnostic techniques that improve patient outcomes and reduce healthcare costs.

The adoption of advanced specimen collection and stabilization technologies is enabling researchers and clinicians to capture rare biomarkers with higher fidelity and stability, enhancing their utility in diagnostics and therapeutic decision-making. However, the high cost associated with these technologies and the lack of skilled personnel in emerging economies remain key challenges. Nonetheless, increasing investments in research and development, coupled with growing awareness of the importance of early diagnosis, are creating significant opportunities for market expansion.

Regionally, North America dominates the Rare Biomarkers Specimen Collection and Stabilization Market, driven by well-established healthcare infrastructure, extensive research funding, and the presence of leading market players. Europe follows closely, benefiting from stringent regulations promoting early diagnosis and personalized treatment. Meanwhile, the Asia Pacific region is anticipated to exhibit the fastest growth, attributed to increasing healthcare investments, rising prevalence of cancer and other chronic diseases, and growing demand for advanced diagnostic tools. Latin America and the Middle East & Africa also show promising potential, supported by improving healthcare access and increased government initiatives.

Major market players included in this report are:

Bio-Rad Laboratories, Inc.
Qiagen N.V.
Thermo Fisher Scientific Inc.
Roche Diagnostics
Agilent Technologies, Inc.
Illumina, Inc.
PerkinElmer Inc.
Bio-Techne Corporation
Guardant Health, Inc.
Menarini Silicon Biosystems
RareCyte, Inc.
Fluxion Biosciences
Foundation Medicine, Inc.
Abcam plc
Creative Bioarray

The detailed segments and sub-segments of the market are explained below:

By Biomarker:

Circulating Cell-Free DNA (ccfDNA)
Circulating Tumor Cells (CTCs)

By End Use:

Hospitals and Diagnostic Laboratories
Academic and Research Institutes
Biopharmaceutical and Biotechnology Companies

By Region:

North America:

U.S.
Canada

Europe:

UK
Germany
France
Spain
Italy
Rest of Europe

Asia Pacific:

China
India
Japan
Australia
South Korea
Rest of Asia Pacific

Latin America:

Brazil
Mexico
Rest of Latin America

Middle East & Africa:

Saudi Arabia
South Africa
Rest of Middle East & Africa

Key Takeaways:

Market Estimates & Forecasts for 10 years from 2022 to 2032.
Regional-level analysis and annualized revenue breakdown for each market segment.
Comprehensive analysis of geographical landscapes with country-level insights across major regions.
Competitive landscape featuring detailed profiles and strategies of major market players.
Insights into key market drivers, challenges, and opportunities.
Actionable recommendations for stakeholders to capitalize on growth prospects.

Chapter 1. Global Rare Biomarkers Specimen Collection and Stabilization Market Executive Summary

1.1. Global Rare Biomarkers Specimen Collection and Stabilization Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Biomarker
- 1.3.2. By End Use
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Rare Biomarkers Specimen Collection and Stabilization Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory Frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Environmental Considerations
  - 2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Rare Biomarkers Specimen Collection and Stabilization Market Dynamics

3.1. Market Drivers
- 3.1.1. Advancements in Precision Medicine
- 3.1.2. Increasing Focus on Early Detection of Rare Diseases
- 3.1.3. Growth in Non-Invasive Diagnostic Techniques
3.2. Market Challenges
- 3.2.1. High Cost of Advanced Technologies
- 3.2.2. Shortage of Skilled Personnel in Emerging Markets
3.3. Market Opportunities
- 3.3.1. Expansion into Emerging Economies
- 3.3.2. Innovations in Specimen Collection Technologies
- 3.3.3. Strategic Collaborations and Partnerships

Chapter 4. Global Rare Biomarkers Specimen Collection and Stabilization Market Industry Analysis

4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Rare Biomarkers Specimen Collection and Stabilization Market Size & Forecasts by Biomarker 2022-2032

5.1. Segment Dashboard
5.2. Global Rare Biomarkers Specimen Collection and Stabilization Market: Biomarker Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 5.2.1. Circulating Cell-Free DNA (ccfDNA)
- 5.2.2. Circulating Tumor Cells (CTCs)

Chapter 6. Global Rare Biomarkers Specimen Collection and Stabilization Market Size & Forecasts by End Use 2022-2032

6.1. Segment Dashboard
6.2. Global Rare Biomarkers Specimen Collection and Stabilization Market: End Use Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 6.2.1. Hospitals and Diagnostic Laboratories
- 6.2.2. Academic and Research Institutes
- 6.2.3. Biopharmaceutical and Biotechnology Companies

Chapter 7. Global Rare Biomarkers Specimen Collection and Stabilization Market Size & Forecasts by Region 2022-2032

7.1. North America Rare Biomarkers Specimen Collection and Stabilization Market
- 7.1.1. U.S. Rare Biomarkers Specimen Collection and Stabilization Market
  - 7.1.1.1. End Use Breakdown Size & Forecasts, 2022-2032
  - 7.1.1.2. Distribution Channel Breakdown Size & Forecasts, 2022-2032
- 7.1.2. Canada Rare Biomarkers Specimen Collection and Stabilization Market
7.2. Europe Rare Biomarkers Specimen Collection and Stabilization Market
- 7.2.1. UK Rare Biomarkers Specimen Collection and Stabilization Market
- 7.2.2. Germany Rare Biomarkers Specimen Collection and Stabilization Market
- 7.2.3. France Rare Biomarkers Specimen Collection and Stabilization Market
- 7.2.4. Spain Rare Biomarkers Specimen Collection and Stabilization Market
- 7.2.5. Italy Rare Biomarkers Specimen Collection and Stabilization Market
- 7.2.6. Rest of Europe Rare Biomarkers Specimen Collection and Stabilization Market
7.3. Asia-Pacific Rare Biomarkers Specimen Collection and Stabilization Market
- 7.3.1. China Rare Biomarkers Specimen Collection and Stabilization Market
- 7.3.2. India Rare Biomarkers Specimen Collection and Stabilization Market
- 7.3.3. Japan Rare Biomarkers Specimen Collection and Stabilization Market
- 7.3.4. Australia Rare Biomarkers Specimen Collection and Stabilization Market
- 7.3.5. South Korea Rare Biomarkers Specimen Collection and Stabilization Market
- 7.3.6. Rest of Asia Pacific Rare Biomarkers Specimen Collection and Stabilization Market
7.4. Latin America Rare Biomarkers Specimen Collection and Stabilization Market
- 7.4.1. Brazil Rare Biomarkers Specimen Collection and Stabilization Market
- 7.4.2. Mexico Rare Biomarkers Specimen Collection and Stabilization Market
- 7.4.3. Rest of Latin America Rare Biomarkers Specimen Collection and Stabilization Market
7.5. Middle East & Africa Rare Biomarkers Specimen Collection and Stabilization Market
- 7.5.1. Saudi Arabia Rare Biomarkers Specimen Collection and Stabilization Market
- 7.5.2. South Africa Rare Biomarkers Specimen Collection and Stabilization Market
- 7.5.3. Rest of Middle East & Africa Rare Biomarkers Specimen Collection and Stabilization Market

Chapter 8. Competitive Intelligence

8.1. Key Company SWOT Analysis
- 8.1.1. Bio-Rad Laboratories, Inc.
- 8.1.2. Qiagen N.V.
- 8.1.3. Thermo Fisher Scientific Inc.
8.2. Top Market Strategies
8.3. Company Profiles
- 8.3.1. Bio-Rad Laboratories, Inc.
  - 8.3.1.1. Key Information
  - 8.3.1.2. Overview
  - 8.3.1.3. Financial (Subject to Data Availability)
  - 8.3.1.4. Product Summary
  - 8.3.1.5. Market Strategies
- 8.3.2. Qiagen N.V.
- 8.3.3. Thermo Fisher Scientific Inc.
- 8.3.4. Roche Diagnostics
- 8.3.5. Agilent Technologies, Inc.
- 8.3.6. Illumina, Inc.
- 8.3.7. PerkinElmer Inc.
- 8.3.8. Bio-Techne Corporation
- 8.3.9. Guardant Health, Inc.
- 8.3.10. Menarini Silicon Biosystems
- 8.3.11. RareCyte, Inc.
- 8.3.12. Fluxion Biosciences
- 8.3.13. Foundation Medicine, Inc.
- 8.3.14. Abcam plc
- 8.3.15. Creative Bioarray

Chapter 9. Research Process

9.1. Research Process
- 9.1.1. Data Mining
- 9.1.2. Analysis
- 9.1.3. Market Estimation
- 9.1.4. Validation
- 9.1.5. Publishing
9.2. Research Attributes